New combo therapy aims to tame stubborn transplant complication
Disease control
Not yet recruiting
This early-phase study tests whether a single dose of specially grown immune cells (EVE-Treg) combined with daily low-dose interleukin-2 can safely treat chronic graft-versus-host disease (cGvHD) that hasn't responded to steroids or IL-2 alone. About 21 people aged 2 and older wh…
Phase: PHASE1 • Sponsor: Leslie Kean • Aim: Disease control
Last updated May 26, 2026 10:35 UTC